Fibrosis-Pipeline Review, H1 2015

Fibrosis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6581IDB
  • |
  • Pages: 151
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Fibrosis-Pipeline Review, H1 2015


Global Markets Direct's, 'Fibrosis-Pipeline Review, H1 2015', provides an overview of the Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Fibrosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Fibrosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Fibrosis Overview 8

Therapeutics Development 9

Pipeline Products for Fibrosis-Overview 9

Pipeline Products for Fibrosis-Comparative Analysis 10

Fibrosis-Therapeutics under Development by Companies 11

Fibrosis-Therapeutics under Investigation by Universities/Institutes 15

Fibrosis-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Fibrosis-Products under Development by Companies 19

Fibrosis-Products under Investigation by Universities/Institutes 22

Fibrosis-Companies Involved in Therapeutics Development 23

Acceleron Pharma, Inc. 23

AiCuris GmbH & Co. KG 24

AnaMar AB 25

Arena Pharmaceuticals, Inc. 26

Bristol-Myers Squibb Company 27

Digna Biotech, S.L. 28

F. Hoffmann-La Roche Ltd. 29

FibroGen, Inc. 30

Five Prime Therapeutics, Inc. 31

Galectin Therapeutics, Inc. 32

GenKyoTex S.A. 33

GlycoMimetics, Inc. 34

HanAll Biopharma Co., Ltd. 35

Intercept Pharmaceuticals, Inc. 36

Isarna Therapeutics GmbH 37

KineMed, Inc. 38

Lycera Corp. 39

MandalMed, Inc. 40

miRagen Therapeutics, Inc. 41

Neumedicines Inc. 42

Pfizer Inc. 43

Promedior, Inc. 44

ProMetic Life Sciences Inc. 45

RuiYi Inc. 46

Scholar Rock, Inc. 47

Siena Biotech S.p.A. 48

SK Chemicals Co., Ltd. 49

Taisho Pharmaceutical Co., Ltd. 50

TRACON Pharmaceuticals, Inc. 51

UCB S.A. 52

Vericel Corporation 53

VivaCell Biotechnology Espana S.L. 54

Fibrosis-Therapeutics Assessment 55

Assessment by Monotherapy Products 55

Assessment by Target 56

Assessment by Mechanism of Action 58

Assessment by Route of Administration 60

Assessment by Molecule Type 62

Drug Profiles 64

AIC-649-Drug Profile 64

AMAP-102-Drug Profile 65

Antibodies for Fibrosis-Drug Profile 67

Antibody to Inhibit Transglutaminase 2 for Fibrosis-Drug Profile 68

APD-371-Drug Profile 69

ASPH-0047-Drug Profile 70

ASPH-1047-Drug Profile 72

Biologics to Inhibit TGF-beta 1 for Fibrosis-Drug Profile 74

disitertide-Drug Profile 75

Drug to Modulate Galectin for Fibrosis, Inflammation and Cancer-Drug Profile 77

G-XXX-Drug Profile 78

Galectin-3C-Drug Profile 79

GC-4419-Drug Profile 81

GKT-136901-Drug Profile 82

HL-156FIB-Drug Profile 84

INT-767-Drug Profile 85

ixmyelocel-T-Drug Profile 87

KBP-7018-Drug Profile 90

MGN-4220-Drug Profile 91

NCE-401-Drug Profile 92

NMIL-121-Drug Profile 93

noscapine-Drug Profile 95

NPH-09-Drug Profile 96

P-006-Drug Profile 97

PBI-4419-Drug Profile 98

PF-06473871-Drug Profile 99

Polysaccharides to Inhibit Galectin for Fibrosis, Inflammation and Cancer-Drug Profile 101

PRI-724-Drug Profile 102

PRM-151-Drug Profile 104

Protein for Fibrosis-Drug Profile 106

Proteins for Fibrosis-Drug Profile 107

Recombinant Protein to Inhibit BMP-1 like Proteinases for Fibrotic Disorders-Drug Profile 108

RYI-018-Drug Profile 109

Small molecule for cancer and fibrotic disease-Drug Profile 110

Small Molecule for Fibrotic Diseases-Drug Profile 111

Small Molecule to Antagonize 5-HT2 Receptor for Cardiovascular, Inflammation, Inflammatory Pain and Fibrosis-Drug Profile 112

Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases-Drug Profile 113

Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis-Drug Profile 114

Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease-Drug Profile 115

Small Molecule to Inhibit LOXL2 for Fibrosis-Drug Profile 116

Small Molecule to Inhibit Rho Kinase for Fibrosis-Drug Profile 117

Small Molecule to Inhibit Tankyrase/Wnt for Musculoskeletal, CNS and Oncology-Drug Profile 118

Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis-Drug Profile 119

Small Molecules to Antagonize S1P3 for Inflammation, Neurodegenerative Diseases and Fibrosis-Drug Profile 120

Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis-Drug Profile 121

Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD-Drug Profile 122

Small Molecules to Inhibit SphK1 for Oncology, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases-Drug Profile 123

SphK2 Program-Drug Profile 124

TRC-205-Drug Profile 125

Trophokine-Drug Profile 126

VCE-0048-Drug Profile 127

Fibrosis-Recent Pipeline Updates 128

Fibrosis-Dormant Projects 142

Fibrosis-Discontinued Products 145

Appendix 146

Methodology 146

Coverage 146

Secondary Research 146

Primary Research 146

Expert Panel Validation 146

Contact Us 146

Disclaimer 147

List of Tables

Number of Products under Development for Fibrosis, H1 2015 13

Number of Products under Development for Fibrosis-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Comparative Analysis by Unknown Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Fibrosis-Pipeline by Acceleron Pharma, Inc., H1 2015 27

Fibrosis-Pipeline by AiCuris GmbH & Co. KG, H1 2015 28

Fibrosis-Pipeline by AnaMar AB, H1 2015 29

Fibrosis-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 30

Fibrosis-Pipeline by Bristol-Myers Squibb Company, H1 2015 31

Fibrosis-Pipeline by Digna Biotech, S.L., H1 2015 32

Fibrosis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 33

Fibrosis-Pipeline by FibroGen, Inc., H1 2015 34

Fibrosis-Pipeline by Five Prime Therapeutics, Inc., H1 2015 35

Fibrosis-Pipeline by Galectin Therapeutics, Inc., H1 2015 36

Fibrosis-Pipeline by GenKyoTex S.A., H1 2015 37

Fibrosis-Pipeline by GlycoMimetics, Inc., H1 2015 38

Fibrosis-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 39

Fibrosis-Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 40

Fibrosis-Pipeline by Isarna Therapeutics GmbH, H1 2015 41

Fibrosis-Pipeline by KineMed, Inc., H1 2015 42

Fibrosis-Pipeline by Lycera Corp., H1 2015 43

Fibrosis-Pipeline by MandalMed, Inc., H1 2015 44

Fibrosis-Pipeline by miRagen Therapeutics, Inc., H1 2015 45

Fibrosis-Pipeline by Neumedicines Inc., H1 2015 46

Fibrosis-Pipeline by Pfizer Inc., H1 2015 47

Fibrosis-Pipeline by Promedior, Inc., H1 2015 48

Fibrosis-Pipeline by ProMetic Life Sciences Inc., H1 2015 49

Fibrosis-Pipeline by RuiYi Inc., H1 2015 50

Fibrosis-Pipeline by Scholar Rock, Inc., H1 2015 51

Fibrosis-Pipeline by Siena Biotech S.p.A., H1 2015 52

Fibrosis-Pipeline by SK Chemicals Co., Ltd., H1 2015 53

Fibrosis-Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 54

Fibrosis-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 55

Fibrosis-Pipeline by UCB S.A., H1 2015 56

Fibrosis-Pipeline by Vericel Corporation, H1 2015 57

Fibrosis-Pipeline by VivaCell Biotechnology Espana S.L., H1 2015 58

Assessment by Monotherapy Products, H1 2015 59

Number of Products by Stage and Target, H1 2015 61

Number of Products by Stage and Mechanism of Action, H1 2015 63

Number of Products by Stage and Route of Administration, H1 2015 65

Number of Products by Stage and Molecule Type, H1 2015 67

Fibrosis Therapeutics-Recent Pipeline Updates, H1 2015 132

Fibrosis-Dormant Projects, H1 2015 146

Fibrosis-Dormant Projects (Contd..1), H1 2015 147

Fibrosis-Dormant Projects (Contd..2), H1 2015 148

Fibrosis-Discontinued Products, H1 2015 149

List of Figures

Number of Products under Development for Fibrosis, H1 2015 13

Number of Products under Development for Fibrosis-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 59

Number of Products by Top 10 Targets, H1 2015 60

Number of Products by Stage and Top 10 Targets, H1 2015 60

Number of Products by Top 10 Mechanism of Actions, H1 2015 62

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 62

Number of Products by Top 10 Routes of Administration, H1 2015 64

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 65

Number of Products by Top 10 Molecule Types, H1 2015 66

Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Acceleron Pharma, Inc.

AiCuris GmbH & Co. KG

AnaMar AB

Arena Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Digna Biotech, S.L.

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

Five Prime Therapeutics, Inc.

Galectin Therapeutics, Inc.

GenKyoTex S.A.

GlycoMimetics, Inc.

HanAll Biopharma Co., Ltd.

Intercept Pharmaceuticals, Inc.

Isarna Therapeutics GmbH

KineMed, Inc.

Lycera Corp.

MandalMed, Inc.

miRagen Therapeutics, Inc.

Neumedicines Inc.

Pfizer Inc.

Promedior, Inc.

ProMetic Life Sciences Inc.

RuiYi Inc.

Scholar Rock, Inc.

Siena Biotech S.p.A.

SK Chemicals Co., Ltd.

Taisho Pharmaceutical Co., Ltd.

TRACON Pharmaceuticals, Inc.


Vericel Corporation

VivaCell Biotechnology Espana S.L.

Fibrosis Therapeutic Products under Development, Key Players in Fibrosis Therapeutics, Fibrosis Pipeline Overview, Fibrosis Pipeline, Fibrosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 136780
Site License
USD 4000 INR 273560
Corporate User License
USD 6000 INR 410340



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]